![Robert A. Hamm](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert A. Hamm
Geen lopende functies
Profiel
Mr. Robert A. Hamm is Chief Operating Officer at Biogen Idec New Ventures, Inc. and Chief Operating Officer & Executive Vice President at Biogen Idec, Inc. He was previously employed as Senior Vice President-Immunology Business Unit by Biogen, Inc. He also served on the board at Inhibitex, Inc. and Syntex Laboratories, Inc.
Mr. Hamm received his undergraduate degree from St. Bonaventure University and a graduate degree from Central Michigan University.
Eerdere bekende functies van Robert A. Hamm
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOGEN INC. | Operationeel Directeur | 31-12-2010 |
Inhibitex LLC
 Inhibitex LLC Pharmaceuticals: MajorHealth Technology Develops drugs | Directeur/Bestuurslid | 01-04-2009 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Develops and manufactures drugs related to immunology, neurobiology and oncology | Corporate Officer/Principal | 01-11-2003 |
Syntex Laboratories, Inc. | Corporate Officer/Principal | 01-04-1994 |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Operationeel Directeur | - |
Opleiding van Robert A. Hamm
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
88
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Develops and manufactures drugs related to immunology, neurobiology and oncology | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Develops drugs | Health Technology |
Central Michigan University
 Central Michigan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Bonaventure University
 St. Bonaventure University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Syntex Laboratories, Inc. |
